<DOC>
	<DOCNO>NCT01464320</DOCNO>
	<brief_summary>To assess safety , tolerability pharmacokinetics ABT-614 subject type 2 diabetes chronic kidney disease albuminuria determine whether ABT-614 reduces glomerular filtration rate .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability ABT-614 Its Effect Kidney Function Subjects With Type 2 Diabetes Chronic Kidney Disease With Protein Their Urine .</brief_title>
	<detailed_description>This Phase 1b , single-site , double-blind , randomize , placebo-controlled study conduct three Periods ; Baseline , Dosing Outpatient . Eligible adult male female subject type 2 diabetes CKD ( chronic kidney disease ) albuminuria select participate . Eighteen subject select participate Baseline Period ensure 16 subject enrol Dosing Period . Subjects eligible Screening confine study site begin Day -2 ( day Baseline Period infusion ) . On Day -1 , subject administer iothalamate infusion measure baseline GFR ( glomerular filtration rate ) . Subjects continue eligible Day 1 randomize 1:1 ratio receive either 10 mg dose ABT-614 matching placebo daily , 15 day . On Day 15 subject administer second iothalamate infusion . Plasma urine sample ABT-614 iothalamate collect . Subjects release confinement Day 20 completion study procedure include 120-hour blood sample collection . Thereafter , subject return outpatient visit Days 25 30 well 30 day last dose study drug . A ± 2 day window permit 30-day Follow-up Visit accommodate subject scheduling .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Inclusion Criteria 1 . Male female age 19 70 year , inclusive , time consent . 2 . Type 2 diabetes receive least one antidiabetic medication least one year time Screening . 3 . Hemoglobin A1c &lt; 12 % time Screening . 4 . Estimated glomerular filtration rate ≥ 30 mL/min calculate CockcroftGault Formula time Screening . 5 . Urinary albumin creatinine ratio 100 5000 mg/g creatinine time Screening . Exclusion Criteria 1 . History unusual allergic reaction iodine , product contain iodine ( example. , iodine contain food ) radioopaque agent . 2 . Subject history epileptic seizure convulsion . 3 . Clinically significant cardiac disease family history longQT syndrome and/or subject and/or family history unexplained , sudden cardiac death . History myocardial infarction coronary artery bypass graft exclusionary occurrence ≥ 12 month prior administration study drug subject conduction abnormality stable without intervention , symptom ischemia increase cardiovascular medication . Electrocardiography ( ECG ) compare historical ensure new clinically significant change occur . 4 . History gastric surgery , cholecystectomy , vagotomy , bowel resection surgical procedure might interfere gastrointestinal motility , potential hydrogen ( pH ) absorption . 5 . Clinically significant respiratory ( except mild asthma ) , gastrointestinal , hematologic , neurologic , thyroid uncontrolled medical illness psychiatric disease disorder . 6 . Screening ECG clinically significant abnormality and/or confirm Screening QTcF prolongation 430 millisecond male 450 millisecond female ECG second third degree atrioventricular block .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Kidney disease</keyword>
</DOC>